Network-based approaches in drug discovery and early development

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 6, 2013, Pages 651-658

  Harrold, J M ^a   Ramanathan, M ^a   Mager, D E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIBIOTIC AGENT; CITALOPRAM; IMATINIB; MEMBRANE RECEPTOR; ROSIGLITAZONE; SMALL INTERFERING RNA;

ANTIBACTERIAL ACTIVITY; ARTICLE; CHEMICAL STRUCTURE; CHRONIC MYELOID LEUKEMIA; DEPRESSION; DRUG APPROVAL; DRUG CLEARANCE; DRUG DESIGN; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; GENE REGULATORY NETWORK; GENOMICS; HUMAN; MATHEMATICAL MODEL; METABOLOMICS; MOLECULAR DYNAMICS; NETWORK LEARNING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACODYNAMICS; PHARMACOPHORE; PRIORITY JOURNAL; PROTEOMICS; SALMONELLA ENTERICA; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEM ANALYSIS; SYSTEMS BIOLOGY; TREATMENT RESPONSE;

ANIMALS; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; DRUG DISCOVERY; GENE REGULATORY NETWORKS; HUMANS; INDIVIDUALIZED MEDICINE; METABOLIC NETWORKS AND PATHWAYS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

EID: 84888011244     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.176     Document Type: Article

References (74)

1. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-715 (2004). (Pubitemid 39173511)
2. Wermuth, C.G. Multitargeted drugs: the end of the "one-target-one- disease" philosophy? Drug Discov. Today 9, 826-827 (2004). (Pubitemid 39286093)
3. Berger, S.I. & Iyengar, R. Network analyses in systems pharmacology. Bioinformatics 25, 2466-2472 (2009).
4. Emig, D. et al. Drug target prediction and repositioning using an integrated network-based approach. PLoS ONE 8, e60618 (2013).
5. Leung, E.L., Cao, Z.W., Jiang, Z.H., Zhou, H. & Liu, L. Network-based drug discovery by integrating systems biology and computational technologies. Brief. Bioinformatics 14, 491-505 (2013).
6. Li, J. et al. Traditional chinese medicine-based network pharmacology could lead to new multicompound drug discovery. Evid. Based Complement. Alternat. Med. 2012, 149762 (2012).
7. Sahin, O. et al. Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance. BMC Syst. Biol. 3, 1 (2009).
8. Csermely, P., Korcsmáros, T., Kiss, H.J., London, G. & Nussinov, R. Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review. Pharmacol. Ther. 138, 333-408 (2013).
9. Pawson, T. & Linding, R. Network medicine. FEBS Lett. 582, 1266-1270 (2008).
10. Sorger, P.K. et al. Quantitative and Systems Pharmacology in the Post-genomic Era: New Approaches to Discovering Drugs and Understanding Therapeutic Mechanisms. An NIH White Paper by the QSP Workshop Group. (2011).http://www.nigms.nih.gov/nr/rdonlyres/8ecb1f7c-be3b-431f-89e6- a43411811ab1/0/systemspharmawpsorger2011.pdf>.
11. Vicini, P. & van der Graaf, P.H. Systems pharmacology for drug discovery and development: paradigm shift or flash in the pan? Clin. Pharmacol. Ther. 93, 379-381 (2013).
12. Zhao, S. & Iyengar, R. Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Annu. Rev. Pharmacol. Toxicol. 52, 505-521 (2012).
13. Morari, M. & Zafiriou, E. Robust Process Control. 488 (Prentice-Hall, Englewood Cliffs, NJ, 1989).
14. Kreeger, P.K. & Lauffenburger, D.A. Cancer systems biology: a network modeling perspective. Carcinogenesis 31, 2-8 (2010).
15. Chakraborty, G., Jain, S. & Kundu, G.C. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 68, 152-161 (2008). (Pubitemid 351380116)
16. Earp, J.C. et al. Modeling corticosteroid effects in a rat model of rheumatoid arthritis I: mechanistic disease progression model for the time course of collagen-induced arthritis in Lewis rats. J. Pharmacol. Exp. Ther. 326, 532-545 (2008).
17. Rowland, M. Physiologically-based pharmacokinetic (PBPK) modeling and simulations principles, methods, and applications in the pharmaceutical industry. CPT Pharmacometrics Syst. Pharmacol. 2, e55 (2013).
18. Hecker, M., Lambeck, S., Toepfer, S., van Someren, E. & Guthke, R. Gene regulatory network inference: data integration in dynamic models-a review. BioSystems. 96, 86-103 (2009).
19. Markowetz, F. & Spang, R. Inferring cellular networks-a review. BMC Bioinformatics 8 (suppl. 6), S5 (2007).
20. Woolf, P.J., Prudhomme, W., Daheron, L., Daley, G.Q. & Lauffenburger, D.A. Bayesian analysis of signaling networks governing embryonic stem cell fate decisions. Bioinformatics 21, 741-753 (2005). (Pubitemid 40439410)
21. Vidal, M. A unifying view of 21st century systems biology. FEBS Lett. 583, 3891-3894 (2009).
22. Riascos, C., Gombert, A. & Pinto, J. A global optimization approach for metabolic flux analysis based on labeling balances. Comput. Chem. Eng. 29, 447-458 (2005). (Pubitemid 40417794)
23. Albert, I., Thakar, J., Li, S., Zhang, R. & Albert, R. Boolean network simulations for life scientists. Source Code Biol. Med. 3, 16 (2008).
24. Assmann, S.M. & Albert, R. Discrete dynamic modeling with asynchronous update, or how to model complex systems in the absence of quantitative information. Methods Mol. Biol. 553, 207-225 (2009).
25. Thakar, J., Pilione, M., Kirimanjeswara, G., Harvill, E.T. & Albert, R. Modeling systems-level regulation of host immune responses. PLoS Comput. Biol. 3, e109 (2007).
26. Grattagliano, I., Bonfrate, L., Diogo, C.V., Wang, H.H., Wang, D.Q. & Portincasa, P. Biochemical mechanisms in drug-induced liver injury: certainties and doubts. World J. Gastroenterol. 15, 4865-4876 (2009).
27. Christophe, T. et al. High content screening identifies decaprenylphosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog. 5, e1000645 (2009).
28. Kanehisa, M. The KEGG database. Novartis Found. Symp. 247, 91-101; discussion 101 (2002).
29. Kanehisa, M., Goto, S., Furumichi, M., Tanabe, M. & Hirakawa, M. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 38, D355-D360 (2010).
30. Caspi, R. et al. The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases. Nucleic Acids Res. 38, D473-D479 (2010).
31. Gao, J., Ellis, L.B. & Wackett, L.P. The University of Minnesota Biocatalysis/Biodegradation Database: improving public access. Nucleic Acids Res. 38, D488-D491 (2010).
32. Chang, A., Scheer, M., Grote, A., Schomburg, I. & Schomburg, D. BRENDA, AMENDA and FRENDA the enzyme information system: new content and tools in 2009. Nucleic Acids Res. 37, D588-D592 (2009).
33. Lee, T.J. et al. BioWarehouse: a bioinformatics database warehouse toolkit. BMC Bioinformatics 7, 170 (2006).
34. Karp, P.D. et al. Pathway Tools version 13.0: integrated software for pathway/genome informatics and systems biology. Brief. Bioinformatics 11, 40-79 (2010).
35. Oprea, T.I., Tropsha, A., Faulon, J.L. & Rintoul, M.D. Systems chemical biology. Nat. Chem. Biol. 3, 447-450 (2007). (Pubitemid 47080379)
36. Campillos, M., Kuhn, M., Gavin, A.C., Jensen, L.J. & Bork, P. Drug target identification using side-effect similarity. Science 321, 263-266 (2008). (Pubitemid 351989100)
37. Kuhn, M., Campillos, M., Letunic, I., Jensen, L.J. & Bork, P. A side effect resource to capture phenotypic effects of drugs. Mol. Syst. Biol. 6, 343 (2010).
38. Keiser, M.J. et al. Predicting new molecular targets for known drugs. Nature 462, 175-181 (2009).
39. Hopkins, A.L. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4, 682-690 (2008).
40. Roth, B.L., Sheffler, D.J. & Kroeze, W.K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 3, 353-359 (2004). (Pubitemid 38499762)
41. Motter, A.E., Nishikawa, T. & Lai, Y.C. Range-based attack on links in scale-free networks: are long-range links responsible for the small-world phenomenon? Phys. Rev. E. Stat. Nonlin. Soft Matter Phys. 66, 065103 (2002).
42. Albert, R. Network inference, analysis, and modeling in systems biology. Plant Cell 19, 3327-3338 (2007).
43. Mason, O. & Verwoerd, M. Graph theory and networks in biology. IET Syst. Biol. 1, 89-119 (2007). (Pubitemid 46488242)
44. Estrada, E. Generalized walks-based centrality measures for complex biological networks. J. Theor. Biol. 263, 556-565 (2010).
45. David-Eden, H. & Mandel-Gutfreund, Y. Revealing unique properties of the ribosome using a network based analysis. Nucleic Acids Res. 36, 4641-4652 (2008).
46. Missiuro, P.V. et al. Information flow analysis of interactome networks. PLoS Comput. Biol. 5, e1000350 (2009).
47. Kitano, H. Towards a theory of biological robustness. Mol. Syst. Biol. 3, 137 (2007).
48. Dijkstra, E.W. A note on two problems in connexion with graphs. Numer. Math. 1, 269-271 (1959).
49. Szallasi, Z., Stelling, J. & Periwal, V. System modeling in cellular biology: from concepts to nuts and Bolts 464 (MIT Press, Cambridge, MA, 2010).
50. Hwang, W.C., Zhang, A. & Ramanathan, M. Identification of information flow-modulating drug targets: a novel bridging paradigm for drug discovery. Clin. Pharmacol. Ther. 84, 563-572 (2008).
51. Cherkassky, B., Goldberg, A. & Radzik, T. Shortest paths algorithms: theory and experimental evaluation. Math. Program. 73, 129-174 (1996). (Pubitemid 126375469)
52. Planes, F.J. & Beasley, J.E. An optimization model for metabolic pathways. Bioinformatics 25, 2723-2729 (2009).
53. Lee, S., Palakornkule, C., Domach, M. & Grossmann, I. Recursive MILP model for finding all the alternate optima in LP models for metabolic networks. Comput. Chem. Eng. 24, 711-716 (2000). (Pubitemid 30608305)
54. Thompson, C.B. Attacking cancer at its root. Cell 138, 1051-1054 (2009).
55. Hanahan, D. & Weinberg, R.A. The hallmarks of cancer. Cell 100, 57-70 (2000). (Pubitemid 30046295)
56. Druker, B.J. & Lydon, N.B. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. 105, 3-7 (2000). (Pubitemid 30036380)
57. Gorre, M.E. et al. Clinical resistance to STI-571 cancer therapy caused by BCRABL gene mutation or amplification. Science 293, 876-880 (2001). (Pubitemid 32743979)
58. Holme, P. & Saramäki, J. Temporal networks. Physics Rep. 519, 97-125 (2011).
59. Becker, D. et al. Robust Salmonella metabolism limits possibilities for new antimicrobials. Nature 440, 303-307 (2006).
60. Kitano, H. A robustness-based approach to systems-oriented drug design. Nat. Rev. Drug Discov. 6, 202-210 (2007). (Pubitemid 46344624)
61. Martens, F.M., Visseren, F.L., Lemay, J., de Koning, E.J. & Rabelink, T.J. Metabolic and additional vascular effects of thiazolidinediones. Drugs 62, 1463-1480 (2002). (Pubitemid 34804155)
62. Schwartz, A.V. & Sellmeyer, D.E. Thiazolidinedione therapy gets complicated: is bone loss the price of improved insulin resistance? Diabetes Care 30, 1670-1671 (2007). (Pubitemid 46871197)
63. Danielson, K.K., Elliott, M.E., LeCaire, T., Binkley, N. & Palta, M. Poor glycemic control is associated with low BMD detected in premenopausal women with type 1 diabetes. Osteoporos. Int. 20, 923-933 (2009).
64. Haffner, S.M., Stern, M.P., Hazuda, H.P., Mitchell, B.D. & Patterson, J.K. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 263, 2893-2898 (1990).
65. Mafong, D.D. & Henry, R.R. The role of incretins in cardiovascular control. Curr. Hypertens. Rep. 11, 18-22 (2009).
66. DeSouza, C. & Fonseca, V. Therapeutic targets to reduce cardiovascular disease in type 2 diabetes. Nat. Rev. Drug Discov. 8, 361-367 (2009).
67. Home, P.D. et al.; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373, 2125-2135 (2009).
68. Bordbar, A., Feist, A.M., Usaite-Black, R., Woodcock, J., Palsson, B.O. & Famili, I. A multi-tissue type genome-scale metabolic network for analysis of wholebody systems physiology. BMC Syst. Biol. 5, 180 (2011).
69. Garriock, H.A. et al. A genomewide association study of citalopram response in major depressive disorder. Biol. Psychiatry 67, 133-138 (2010).
70. Goh, K.I., Cusick, M.E., Valle, D., Childs, B., Vidal, M. & Barabási, A.L. The human disease network. Proc. Natl. Acad. Sci. USA 104, 8685-8690 (2007). (Pubitemid 47175372)
71. Harrold, J.M., Straubinger, R.M. & Mager, D.E. Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamics. Cancer Res. 72, 1632-1641 (2012).
72. Kirouac, D.C. et al. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors. Sci. Signal. 6, ra68 (2013).
73. Liu, Y.Y., Slotine, J.J. & Barabási, A.L. Observability of complex systems. Proc. Natl. Acad. Sci. USA 110, 2460-2465 (2013).
74. Iyengar, R., Zhao, S., Chung, S.W., Mager, D.E. & Gallo, J.M. Merging systems biology with pharmacodynamics. Sci. Transl. Med. 4, 126ps7 (2012).